Cell line · CVCL_8878
Papers34
1 to 20 of 34
Download this page as JSON| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| Extracellular vesicle lipidomics liquid biopsy reveals systemic and tumor microenvironment metabolic reprogramming in ovarian cancer. | Mol Oncol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Patient-derived model capturing hypoxia and extracellular matrix remodelling of immunologically cold high-grade serous tumours. | Nat Commun | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Framework for evaluating in vitro vasculogenic mimicry using structural and metabolic parameters. | Cell Rep Methods | 2026 | Its Methods give the RRID and name the line | PubMed | |
| KPNA2 Drives Immunosuppression in Ovarian Cancer via CCL2/CCR2-Dependent MDSC Recruitment. | Cancer Sci | 2026 | Its Methods give the RRID and name the line | PubMed | |
| BMAL2 is a druggable target for ovarian clear cell carcinoma (OCCC). | EMBO Mol Med | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Platelets induce VISTA expression and modulate the ovarian tumor microenvironment. | Platelets | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Machine learning-based development of a cytotoxicity prediction model for NK cell therapy in cancers. | Cell Oncol (Dordr) | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Epigenetic modulation of BARD1 to enhance anti-VEGF therapy. | Cell Rep Med | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Spatiotemporal analysis of ratiometric biosensors in live multicellular spheroids using SPoRTS. | Cell Rep Methods | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Vertical inhibition of p110α/AKT and N-cadherin enhances treatment efficacy in PIK3CA-aberrated ovarian cancer cells. | Mol Oncol | 2025 | Its Methods give the RRID and name the line | PubMed | |
| The anti-tumor effects of AZD4547 on ovarian cancer cells: differential responses based on c-Met and FGF19/FGFR4 expression. | Cancer Cell Int | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Cyclooxygenase-2 Blockade Is Crucial to Restore Natural Killer Cell Activity before Anti-CTLA-4 Therapy against High-Grade Serous Ovarian Cancer. | Cancers (Basel) | 2023 | Its Methods give the RRID and name the line | PubMed | |
| A NOTCH1 Mutation Found in a Newly Established Ovarian Cancer Cell Line (FDOVL) Promotes Lymph Node Metastasis in Ovarian Cancer. | Int J Mol Sci | 2023 | Its Methods give the RRID and name the line | PubMed | |
| Exploiting metabolic vulnerabilities after anti-VEGF antibody therapy in ovarian cancer. | iScience | 2023 | Its Methods give the RRID and name the line | PubMed | |
| Development and Utility of a PAK1-Selective Degrader. | J Med Chem | 2022 | Its Methods give the RRID and name the line | PubMed | |
| G6PD inhibition sensitizes ovarian cancer cells to oxidative stress in the metastatic omental microenvironment. | Cell Rep | 2022 | Its Methods give the RRID and name the line | PubMed | |
| The oncoprotein BCL6 enables solid tumor cells to evade genotoxic stress. | Elife | 2022 | Its Methods give the RRID and name the line | PubMed | |
| Rational Combination of CRM1 Inhibitor Selinexor and Olaparib Shows Synergy in Ovarian Cancer Cell Lines and Mouse Models. | Mol Cancer Ther | 2021 | Its Methods give the RRID and name the line | PubMed | |
| The Ratio of Toxic-to-Nontoxic miRNAs Predicts Platinum Sensitivity in Ovarian Cancer. | Cancer Res | 2021 | Its Methods give the RRID and name the line | PubMed | |
| Quantitative Proteomics of the Cancer Cell Line Encyclopedia. | Cell | 2020 | Cellosaurus cites it | PubMed |
cell-lines-2026-11-14-0.1.0
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_8878/papers